Biogen Inc. (biib)
BIIB — Company Overview
Investors tracking BIIB follow a Drug Manufacturers - General name listed on NMS within Healthcare.
| Ticker | BIIB |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NMS |
| Market cap | $33.62B |
| Last price | $227.53 |
| Size category | Large Cap |
BIIB — Business Description
The business profile of Biogen Inc. (BIIB) reflects its role in Drug Manufacturers - General. Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphom…
Official website: https://www.biogen.com.
BIIB — Investment Thesis
Biogen Inc. (BIIB) attracts investors weighing Drug Manufacturers - General fundamentals against current market pricing.
- Revenue is expanding at roughly 3.4% year-over-year (public data).
- Trailing P/E of 39.30× implies elevated growth expectations at the current price.
- Forward P/E (13.76×) is below trailing P/E — earnings may be expected to improve.
- Equity market capitalization is approximately $33.62B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
BIIB — Financial Health
BIIB financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin near 8.3% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $1.27B supports balance-sheet flexibility.
| Trailing P/E | 39.30× |
| Forward P/E | 13.76× |
| Price / Sales | 3.35× |
| Price / Book | 1.78× |
| Gross margin | 78.3% |
| Operating margin | 25.1% |
| Profit margin | 8.3% |
| Return on equity | 4.6% |
| Debt / Equity | 44.33 |
| Free cash flow | $1.27B |
BIIB — Growth Outlook
Growth outlook for Biogen Inc. (BIIB) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 3.4% suggests steady but measured expansion.
- Earnings declined -84.8% year-over-year — margin or volume pressure may be in play.
- Price is 0.7% below the 52-week high.
BIIB — Competitive Position
Biogen Inc. (BIIB) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $33.62B places BIIB among large-cap peers.
- Gross margin near 78.3% may reflect pricing power or favorable mix.
BIIB — Strengths
Strengths for Biogen Inc. (BIIB) inferred from public financial metrics:
- Gross margin of 78.3% supports competitive unit economics.
- Positive free cash flow ($1.27B).
- Moderate leverage (debt/equity 44.33).
- Large Cap scale ($33.62B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
BIIB — Weaknesses
Weaknesses and pressure points for Biogen Inc. (BIIB) based on available data:
- Earnings decline of -84.8% year-over-year.
- Elevated trailing P/E (39.30×) limits valuation margin of safety.
BIIB — Opportunities
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
BIIB — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
BIIB — Summary
Biogen Inc. (BIIB) is a large-cap Healthcare company focused on Drug Manufacturers - General, listed on NMS. Last price $227.53 with market cap $33.62B. Trailing P/E 39.30×. Revenue grew 3.4% year-over-year per public data. Notable strengths include gross margin of 78.3% supports competitive unit economics. Key watch items include earnings decline of -84.8% year-over-year. Review free estimates and earnings pages for BIIB; upgrade for institutional ownership and live headlines.
Start Free — open BIIB in Vest Terminal
Access live data, filings, ownership, and analysis for Biogen Inc..
Biogen Inc. FAQ
What does Biogen Inc. (BIIB) do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYC…
What is BIIB's P/E ratio?
Biogen Inc. has a trailing P/E of 39.30× based on publicly available market data.
Does BIIB pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is BIIB in?
Biogen Inc. is classified in Healthcare (Drug Manufacturers - General) on NMS.
What is BIIB's market capitalization?
Approximate market cap: $33.62B.
What are the main risks for BIIB?
Key risks include elevated valuation, among factors on this page.
What are the strengths of BIIB?
Potential positives include gross margin of 78.3% supports competitive unit economics, positive free cash flow ($1.27b).
Where can I get analyst estimates for BIIB?
Public analyst price targets and consensus for Biogen Inc. are on the free /stocks/biib/estimates page. Deeper estimate history and models are available in Vest Terminal.